IOVA - Iovance Biotherapeutics Inc. (IOVA) Q1 2024 Earnings Call Transcript
2024-05-09 20:40:27 ET
Iovance Biotherapeutics, Inc. (IOVA)
Q1 2024 Results Conference Call
May 09, 2024 04:30 PM ET
Company Participants
Sara Pellegrino - Senior Vice President, Investor Relations & Corporate Communications
Dr. Fred Vogt - Interim President & Chief Executive Officer
Jim Ziegler - Executive Vice President, Commercial
Dr. Igor Bilinsky - Chief Operating Officer
Jean-Marc Bellemin - Chief Financial Officer
Dr. Friedrich Finckenstein - Chief Medical Officer
Dr. Brian Gastman - Executive Vice President, Medical Affairs
Dr. Raj Puri - Executive Vice President, Regulatory Strategy & Translational Medicine
Conference Call Participants
Michael Yee - Jefferies
Andrea Tan - Goldman Sachs
Peter Lawson - Barclays
Tyler Van Buren - TD Cowen
Yanan Zhu - Wells Fargo Securities
Colleen Kusy - Baird
Asthika Goonewardene - Truist
Joe Catanzaro - Piper Sandler
Reni Benjamin - JMP Securities
Ben Burnett - Stifel
Presentation
Operator
Welcome to the Iovance Biotherapeutics Conference Call to discuss the First Quarter 2024 Results and recent Corporate Updates. My name is Livia, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded.
I will now hand the conference call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sarah, you may begin.
Sara Pellegrino
Thank you, operator. Good afternoon and thank you for joining this conference call and webcast to discuss our first quarter 2024 results and recent corporate update.
Dr. Fred Vogt, our Interim President and Chief Executive Officer will provide an introduction and summarize key updates on our U.S. Commercial launch of Amtagvi and our pipeline program.
Jim Ziegler, EVP Commercial, will highlight our initial insights for the U.S. commercial launch of Amtagvi, in advanced melanoma. Dr. Igor Bilinsky, COO, will highlight commercial manufacturing and capacity expansion plans. Jean-Marc Bellemin, CFO will review our financial results....
Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Earnings Call Transcript